These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38546916)

  • 1. Extracellular matrix protein 1 (ECM1) is a potential biomarker in B cell acute lymphoblastic leukemia.
    Wu LX; Zhao MY; Yan N; Zhou YL; Cao LM; Qin YZ; Jiang Q; Xu LP; Zhang XH; Huang XJ; Jiang H; Ruan GR
    Clin Exp Med; 2024 Mar; 24(1):56. PubMed ID: 38546916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High frequency of heat shock protein 27 overexpression is a highly effective, high-coverage marker for minimal residual disease detection in children with B-cell acute lymphoblastic leukemia.
    Chou SW; Su YH; Lu MY; Chang HH; Yang YL; Lin DT; Lin KH; Coustan-Smith E; Jou ST
    Pediatr Blood Cancer; 2023 Jan; 70(1):e29990. PubMed ID: 36250996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CRLF2 and IKZF1 abnormalities in Mexican children with acute lymphoblastic leukemia and recurrent gene fusions: exploring surrogate markers of signaling pathways.
    Moreno Lorenzana D; Juárez Velázquez MDR; Reyes León A; Martínez Anaya D; Hernández Monterde A; Salas Labadía C; Navarrete Meneses MDP; Zapata Tarrés M; Juárez Villegas L; Jarquín Ramírez B; Cárdenas Cardós R; Herrera Almanza M; Paredes Aguilera R; Pérez Vera P
    J Pathol Clin Res; 2021 Jul; 7(4):410-421. PubMed ID: 33890726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Two Quantitative PCR-Based Assays for Detection of Minimal Residual Disease in B-Precursor Acute Lymphoblastic Leukemia Harboring Three Major Fusion Transcripts.
    Huang YJ; Kuo MC; Jaing TH; Liu HC; Yeh TC; Chen SH; Lin TL; Yang CP; Wang PN; Sheen JM; Chang TK; Chang CH; Hu SF; Huang TY; Wang SC; Wu KH; Chiou SS; Hsiao CC; Shih LY
    J Mol Diagn; 2021 Oct; 23(10):1373-1379. PubMed ID: 34325057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical Significance of Minimal Residual Disease in Pediatric Patients with
    Xue YJ; Lu AD; Wang Y; Jia YP; Zuo YX; Zhang LP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1303-1308. PubMed ID: 37846676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic alterations and MRD refine risk assessment for KMT2A-rearranged B-cell precursor ALL in adults: a GRAALL study.
    Kim R; Bergugnat H; Pastoret C; Pasquier F; Raffoux E; Larcher L; Passet M; Grardel N; Delabesse E; Kubetzko S; Caye-Eude A; Meyer C; Marschalek R; Lafage-Pochitaloff M; Thiebaut-Bertrand A; Balsat M; Escoffre-Barbe M; Blum S; Baumann M; Banos A; Straetmans N; Gallego-Hernanz MP; Chalandon Y; Graux C; Soulier J; Leguay T; Hunault M; Huguet F; Lhéritier V; Dombret H; Boissel N; Clappier E
    Blood; 2023 Nov; 142(21):1806-1817. PubMed ID: 37595275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flow cytometric predictive scoring systems for common fusions ETV6/RUNX1, BCR/ABL1, TCF3/PBX1 and rearrangements of the KMT2A gene, proposed for the initial cytogenetic approach in cases of B-acute lymphoblastic leukemia.
    Tsagarakis NJ; Papadhimitriou SI; Pavlidis D; Marinakis T; Kostopoulos IV; Stiakaki E; Polychronopoulou S; Paterakis G
    Int J Lab Hematol; 2019 Jun; 41(3):364-372. PubMed ID: 30730614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging molecular subtypes and therapies in acute lymphoblastic leukemia.
    Davis K; Sheikh T; Aggarwal N
    Semin Diagn Pathol; 2023 May; 40(3):202-215. PubMed ID: 37120350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of IKZF1 deletion in adults with common B-cell acute lymphoblastic leukemia.
    Yao QM; Liu KY; Gale RP; Jiang B; Liu YR; Jiang Q; Jiang H; Zhang XH; Zhang MJ; Chen SS; Huang XJ; Xu LP; Ruan GR
    BMC Cancer; 2016 Apr; 16():269. PubMed ID: 27067989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A surrogate molecular approach for the detection of Philadelphia chromosome-like B-acute lymphoblastic leukemia.
    Gupta DG; Varma N; Abdulkadir SA; Sreedharanunni S; Sachdeva MUS; Naseem S; Bose P; Binota J; Malhotra P; Khadwal A; Trehan A; Varma S
    Cancer; 2024 Mar; 130(5):713-726. PubMed ID: 37819686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of IKZF1 deletions and IKZF1
    Braun M; Pastorczak A; Sędek Ł; Taha J; Madzio J; Jatczak-Pawlik I; Wypyszczak K; Matysiak M; Derwich K; Lejman M; Kazanowska B; Szczepański T; Kowalczyk JR; Mlynarski W;
    Hematol Oncol; 2022 Aug; 40(3):430-441. PubMed ID: 35118711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic landscape of B-other acute lymphoblastic leukemia in an adult retrospective cohort with a focus on
    Hrabovsky S; Vrzalova Z; Stika J; Jelinkova H; Jarosova M; Navrkalova V; Martenek J; Folber F; Salek C; Horacek JM; Pospisilova S; Mayer J; Doubek M
    Acta Oncol; 2021 Jun; 60(6):760-770. PubMed ID: 33750258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of IKZF1 deletion in adult B cell acute lymphoblastic leukemia: a meta-analysis.
    Zhang W; Kuang P; Li H; Wang F; Wang Y
    Ann Hematol; 2017 Feb; 96(2):215-225. PubMed ID: 27815723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome of TCF3-PBX1 positive pediatric acute lymphoblastic leukemia patients in Japan: a collaborative study of Japan Association of Childhood Leukemia Study (JACLS) and Children's Cancer and Leukemia Study Group (CCLSG).
    Asai D; Imamura T; Yamashita Y; Suenobu S; Moriya-Saito A; Hasegawa D; Deguchi T; Hashii Y; Endo M; Hatakeyama N; Kawasaki H; Hori H; Horibe K; Yumura-Yagi K; Hara J; Watanabe A; Kikuta A; Oda M; Sato A;
    Cancer Med; 2014 Jun; 3(3):623-31. PubMed ID: 24578304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ikaros family zinc-finger 1 mutation is an independent factor for the poor prognosis of adult B-cell acute lymphoblastic leukemia, and allogeneic hematopoietic stem cell transplantation can improve clinical outcomes.
    Tang S; Shen H; Qu C; Dai H; Zhu X; Xue S; Ding Z; Lu J; Wu D; Tang X
    Bone Marrow Transplant; 2019 Feb; 54(2):236-243. PubMed ID: 29942002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001.
    Vrooman LM; Blonquist TM; Harris MH; Stevenson KE; Place AE; Hunt SK; O'Brien JE; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Sulis ML; Welch JJG; Neuberg DS; Sallan SE; Silverman LB
    Blood Adv; 2018 Jun; 2(12):1449-1458. PubMed ID: 29941458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD304/neuropilin-1 is a very useful and dependable marker for the measurable residual disease assessment of B-cell precursor acute lymphoblastic leukemia.
    Gudapati P; Khanka T; Chatterjee G; Ghogale S; Badrinath Y; Deshpande N; Patil J; Narula G; Shetty D; Banavali S; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
    Cytometry B Clin Cytom; 2020 Jul; 98(4):328-335. PubMed ID: 31944572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplant measurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the EBMT.
    Esteve J; Giebel S; Labopin M; Czerw T; Wu D; Volin L; Socié G; Yakoub-Agha I; Maertens J; Cornelissen JJ; Pigneux A; Shimoni A; Schwerdtfeger R; Labussière-Wallet H; Russell N; Schattenberg A; Chevallier P; Koza V; Foà R; Schmid C; Peric Z; Mohty M; Nagler A
    Leukemia; 2021 Aug; 35(8):2232-2242. PubMed ID: 33542481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular genetic profile in BCR-ABL1 negative pediatric B-cell acute lymphoblastic leukemia can further refine outcome prediction in addition to that by end-induction minimal residual disease detection.
    Gupta SK; Bakhshi S; Chopra A; Kamal VK
    Leuk Lymphoma; 2018 Aug; 59(8):1899-1904. PubMed ID: 29199525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients.
    Scheijen B; Boer JM; Marke R; Tijchon E; van Ingen Schenau D; Waanders E; van Emst L; van der Meer LT; Pieters R; Escherich G; Horstmann MA; Sonneveld E; Venn N; Sutton R; Dalla-Pozza L; Kuiper RP; Hoogerbrugge PM; den Boer ML; van Leeuwen FN
    Haematologica; 2017 Mar; 102(3):541-551. PubMed ID: 27979924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.